Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Innoscripta SE is a software company specializing in application software with a primary focus on software-as-a-service (SaaS) solutions for research and development (R&D) tax incentives and project management. Founded in 2012 and headquartered in Munich, Germany, the company has established itself as a leading provider of digital platforms that streamline R&D project workflows, facilitate time tracking, funding management, and ensure audit-proof documentation for regulatory compliance. Its technologies are particularly significant for companies seeking to optimize their utilization of government-backed R&D funding and tax credits, addressing compliance complexities and enabling efficient resource allocation across industries. The company’s integrated 360° platform leverages automation and AI-driven insights, empowering enterprises to manage various aspects of the R&D lifecycle in a single system. Innoscripta SE plays a crucial role in the information technology and software sector, supporting innovation-driven businesses throughout Germany and beyond by simplifying access to R&D funding in a rapidly evolving market exceeding 100 billion euros in value. The company is recognized for continuous innovation and a strong commitment to operational excellence and sustainable growth within the R&D tax compliance ecosystem.
Margins and capital returns are both well above average: 61.39% operating margin, ROIC at 78.82%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue up 59.8% YoY with margins expanding 3.7pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
€118M
▲ +59.8% YoY
Net Income (TTM)
€50M
▲ +69.8% YoY
Op. Margin
63.05%
▲ +3.7pp YoY
ROIC
78.82%
▲ +5.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€67M
▲ +103.2% YoY
Op. Cash Flow (TTM)
€67M
▲ +103.7% YoY
Net Debt
-€34M
Net Cash Position
Cash & Equiv.
€47M
Continue Research